Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Hepatocellular 16Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Liver Neoplasms 2Cholangiocarcinoma 2Advanced Endometrial Cancer 2Thyroid Neoplasms 1Solid Tumors 1Recurrence 1Neoplasm Metastasis 1Hepatitis B 1Esophageal Squamous Cell Carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Clear-cell metastatic renal cell carcinoma 1Cirrhosis, Familial, with Pulmonary Hypertension 1Breast Neoplasms 1Bone Neoplasms 1BTC 1Advanced Triple Negative Breast Cancer 1Advanced Non-squamous Non-small-cell Lung Cancer 1Advanced Hepatocellular Carcinoma (HCC) 1Adenocarcinoma 1

Interventions

lenvatinib 1camrelizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Triple Negative Breast Cancer × lenvatinib × Clear all
NCT06849492 2025-02-27

SHIFT-001

Fudan University

Phase 2 Not yet recruiting
120 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡